Breaking News Instant updates and real-time market news.

MYL

Mylan

$35.57

-0.08 (-0.22%)

, AGN

Allergan

$171.85

-1.53 (-0.88%)

16:12
07/20/18
07/20
16:12
07/20/18
16:12

PTAB rules in favor of Mylan to allow Restasis challenge to proceed

Mylan (MYL) announced that the U.S. Court of Appeals for the Federal Circuit affirmed the decision of the U.S. Patent Trial and Appeal Board, PTAB, which found that tribal sovereign immunity cannot apply to prevent inter partes review proceedings. Today's decision allows Mylan's IPR challenges to Allergan's (AGN) Restasis patents to proceed. In a move admittedly designed to protect the Restasis(R) patents from cancellation by the PTAB, Allergan assigned the rights of six patents to the Saint Regis Mohawk Tribe. The Tribe then moved to dismiss the proceedings, arguing that its tribal sovereign immunity prevented the PTAB from reviewing the patents. Mylan CEO Heather Bresch commented, "This win is a victory in our ongoing efforts to stop patent abuses by brand companies and to help drive access to more affordable medicine. Today's ruling reaffirms that Allergan's attempt to leverage the Saint Regis Mohawk Tribe for patent protection represents another inappropriate tactic to delay the availability of generic medicines for patients who need them. Mylan will continue to do its part to fight these types of abuses and to restore the careful balance between innovation and access that is so important to ensuring a sustainable U.S. healthcare system."

MYL

Mylan

$35.57

-0.08 (-0.22%)

AGN

Allergan

$171.85

-1.53 (-0.88%)

  • 26

    Jul

  • 13

    Nov

MYL Mylan
$35.57

-0.08 (-0.22%)

06/27/18
SBSH
06/27/18
NO CHANGE
SBSH
Buy
Mylan share price reaction following delay news 'overdone,' says Citi
Citi analyst Liav Abraham removed Mylan from his US Focus List, telling investors in a research note that he remains "constructive" on Mylan the recent FDA approval of Fulphila and slight delay to the approval of generic Advair, and says he views the recent share price reaction following the delay announcement as "overdone." He still expects to see potential approval in the latter part of 2018.
07/12/18
GSCO
07/12/18
DOWNGRADE
Target $74
GSCO
Sell
Perrigo downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Jami Rubin downgraded Perrigo (PRGO) to Sell and lowered her price target for the shares to $74 from $78. The analyst sees "no meaningful risk" to estimates but expects the "business to drift" due to a lack of meaningful new launches in the pipeline. The market may also attribute a lower multiple to Perrigo's consumer business as rates rise, which creates downside risk to the equity, Rubin tells investors in a research note. She sees more upside in other stocks, namely Mylan (MYL) and Teva (TEVA).
07/12/18
JEFF
07/12/18
NO CHANGE
Target $200
JEFF
Buy
Mlyan priced Amgen biosimilar at 33% discount, says Jefferies
Jefferies analyst Michael Yee says Mylan (MYL) priced its biosimilar to Amgen's Neulasta at a 33% discount to the gross price of branded Neulasta. While the discount is slightly more than initial expectations of 10%-20%, the key is knowing what level of rebating Mylan will be offering to hospitals, Yee tells investors in a research note. The analyst admits, however, that Mylan's Fulphila price "indeed undercuts" Amgen. He keeps a Buy rating on Amgen shares with a $200 price target.
07/18/18
WELS
07/18/18
NO CHANGE
WELS
Novartis report has negative read through for Teva, Mylan, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis (NVS) lowered its 2018 guidance for Sandoz along with its Q2 report and reportedly told Bloomberg that it would consider selling the generic drug unit. He sees a negative read through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL), from Novartis' report, Maris tells investors. He also noted that Novartis said it will not increase prices on its drugs in the U.S. for the rest of 2018, as Pfizer (PFE) recently has also said, calling this "a wise approach and correct read of the increasing intensity of the scrutiny around rising healthcare costs." Maris continues to expect the " chilling effect" on price increases to spread through the industry. Lastly, the analyst pointed out that the Amgen-partnered (AMGN) launch of Aimovig is off to a strong start, which he believes bodes well for Teva's fremanezumab and Eli Lilly's (LLY) galcanezumab.
AGN Allergan
$171.85

-1.53 (-0.88%)

07/09/18
MZHO
07/09/18
NO CHANGE
Target $194
MZHO
Neutral
Allergan price target raised to $194 from $176 at Mizuho
Mizuho analyst Irina Koffler raised her price target for Allergan to $194 after extending her model to 2025 to "assess the beneficial impact" of the company's pipeline. Her new price target reflects a long-term outlook but the analyst reiterates a Neutral rating on Allergan.
07/12/18
CANT
07/12/18
INITIATION
Target $59
CANT
Overweight
Cantor puts $59 price target on 'undervalued' NASH play Galmed
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of Galmed Pharmaceuticals (GLMD) with an Overweight rating and $59 price target. The stock closed yesterday down 45c to $10.55. The company is developing Aramchol, a novel, once-daily, oral therapy to treat liver diseases using fattyacid/bile-acid conjugates, Piros tells investors in a research note. The analyst believes that by Q4 of 2019, only three meaningful non-alcoholic steatohepatitis pivotal programs will be in development: Allergan's (AGN) cenicriviroc, Madrigal Pharmaceuticals' (MDGL) MGL-3196, and Galmed's Aramchol. Of the three drugs, Galmed's has the highest likelihood of achieving improvement on NASH resolution without worsening of fibrosis, and improvement in fibrosis score without worsening of NASH, Piros argues. He believes Galmed is undervalued relative to peers in the NASH space.
07/19/18
PIPR
07/19/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron overhang 'effectively lifted' after Allergan data, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond noted that Allergan (AGN) and Molecular Partners disclosed data from two Phase 3 trials comparing the latest DARPin formulation to Lucentis in age-related macular degeneration, calling the data "decidedly a non-starter." While few Regeneron (REGN) investors have expressed concern to Raymond over looming DARPin data, any overhang that did exist due to worries about another potential Eylea competitor in the AMD space have "been effectively lifted" following the DARPin data, said the analyst. He remains a buyer of Regeneron shares and keeps an Overweight rating and $450 price target on the stock.
07/19/18
WELS
07/19/18
NO CHANGE
Target $240
WELS
Outperform
Allergan wet AMD data exceed 'unofficial benchmark,' says Wells Fargo
The released efficacy data from Allergan's (AGN) two Phase III trials of its anti-VEGF treatment abicipar in wet age-related macular degeneration looks to have exceeded the "unofficial benchmark set by potential extended-duration competitors," Novartis' (NVS) brolucizumab and Regeneron's (REGN) Eylea, Wells Fargo analyst David Maris tells investors in a research note. The analyst forecasts $125M in sales for abicipar in its first year on the market in 2020 and estimates it will grow to $500M in 2022. Maris keeps an Outperform rating on Allergan with a $240 price target.

TODAY'S FREE FLY STORIES

03:30
08/15/18
08/15
03:30
08/15/18
03:30
General news
FX Action: USD-CAD found support at yesterday's three-session low »

FX Action: USD-CAD found…

02:20
08/15/18
08/15
02:20
08/15/18
02:20
General news
FX Update: The Dollar has posted broad gains »

FX Update: The Dollar has…

01:55
08/15/18
08/15
01:55
08/15/18
01:55
General news
Asian Market Wrap: »

Asian Market Wrap:…

SPWR

SunPower

$6.89

-0.09 (-1.29%)

, SUNEQ

SunEdison

$0.00

(0.00%)

21:08
08/14/18
08/14
21:08
08/14/18
21:08
Periodicals
China lodges WTO complaint about U.S. solar tariffs, Reuters says »

China Commerce Ministry…

SPWR

SunPower

$6.89

-0.09 (-1.29%)

SUNEQ

SunEdison

$0.00

(0.00%)

CSIQ

Canadian Solar

$13.33

-0.27 (-1.99%)

JASO

JA Solar

$0.00

(0.00%)

TSL

Trina Solar

$0.00

(0.00%)

FSLR

First Solar

$52.01

-0.48 (-0.91%)

SCTY

Bought by TSLA

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

GS

Goldman Sachs

$229.53

2.7 (1.19%)

20:39
08/14/18
08/14
20:39
08/14/18
20:39
Periodicals
Judge allows Goldman shareholders to pursue 2008 CDO class action, Reuters says »

U.S. District Court judge…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$41.87

1.79 (4.47%)

, PFGC

Performance Food Group

$37.60

0.7 (1.90%)

20:25
08/14/18
08/14
20:25
08/14/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

M

Macy's

$41.87

1.79 (4.47%)

PFGC

Performance Food Group

$37.60

0.7 (1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 15

    Aug

  • 17

    Sep

FAF

First American

$56.46

0.04 (0.07%)

20:16
08/14/18
08/14
20:16
08/14/18
20:16
Hot Stocks
First American raises quarterly dividend by 11% to 42c per share »

The cash dividend is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

BAS

Basic Energy

$8.61

-0.11 (-1.26%)

20:12
08/14/18
08/14
20:12
08/14/18
20:12
Hot Stocks
Basic Energy names David Schorlemer as new CFO »

Basic Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

MRT

MedEquities Realty Trust

$10.00

0.16 (1.63%)

19:45
08/14/18
08/14
19:45
08/14/18
19:45
Periodicals
MedEquities Realty Trust exploring a sale, Bloomberg reports »

MedEquities Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$9.50

0.04 (0.42%)

19:26
08/14/18
08/14
19:26
08/14/18
19:26
Periodicals
Ford plans to invest $740M to revamp Detroit station, other sites, Reuters says »

Ford said it plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 31

    Aug

PETQ

PetIQ

$28.26

1 (3.67%)

, PRSP

Perspecta

$21.64

-0.31 (-1.41%)

19:00
08/14/18
08/14
19:00
08/14/18
19:00
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: PetIQ…

PETQ

PetIQ

$28.26

1 (3.67%)

PRSP

Perspecta

$21.64

-0.31 (-1.41%)

FENG

Phoenix New Media

$4.12

-0.055 (-1.32%)

EGN

Energen

$73.15

1.76 (2.47%)

FANG

Diamondback Energy

$133.75

1.84 (1.39%)

ADNT

Adient

$42.65

0.19 (0.45%)

ERI

Eldorado Resorts

$43.85

0.55 (1.27%)

TEVA

Teva

$22.12

0.17 (0.77%)

CASA

Casa Systems

$15.62

-0.17 (-1.08%)

A

Agilent

$66.72

0.77 (1.17%)

CREE

Cree

$50.17

-0.11 (-0.22%)

VRAY

ViewRay

$9.89

-0.01 (-0.10%)

CRZO

Carrizo Oil & Gas

$24.31

0.62 (2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 19

    Aug

  • 21

    Aug

  • 28

    Aug

  • 04

    Sep

  • 10

    Sep

  • 16

    Sep

  • 15

    Aug

  • 15

    Aug

AAP

Advance Auto Parts

$156.01

11.22 (7.75%)

18:47
08/14/18
08/14
18:47
08/14/18
18:47
Upgrade
Advance Auto Parts rating change at Citi »

Advance Auto Parts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

SPHS

Sophiris Bio

$2.74

0.13 (4.98%)

18:37
08/14/18
08/14
18:37
08/14/18
18:37
Recommendations
Sophiris Bio analyst commentary at Piper Jaffray »

Sophiris Bio topsalycin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$52.87

0.65 (1.24%)

, GOOG

Alphabet

$1,241.95

6.85 (0.55%)

18:30
08/14/18
08/14
18:30
08/14/18
18:30
Hot Stocks
Verizon to partner with YouTube TV for 5G residential broadband package »

Verizon (VZ) announced it…

VZ

Verizon

$52.87

0.65 (1.24%)

GOOG

Alphabet

$1,241.95

6.85 (0.55%)

GOOGL

Alphabet Class A

$1,258.15

9.39 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 14

    Aug

  • 22

    Aug

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

NVDA

Nvidia

$261.47

5.39 (2.10%)

18:27
08/14/18
08/14
18:27
08/14/18
18:27
Upgrade
Nvidia rating change at Wells Fargo »

Nvidia double-upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

ORCL

Oracle

$48.23

0.21 (0.44%)

, RMNI

Rimini Street

$6.01

0.11 (1.86%)

18:26
08/14/18
08/14
18:26
08/14/18
18:26
Hot Stocks
Court grants Oracle's motion for permanent injunction against Rimini Street »

For the second time, a…

ORCL

Oracle

$48.23

0.21 (0.44%)

RMNI

Rimini Street

$6.01

0.11 (1.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$261.47

5.39 (2.10%)

18:22
08/14/18
08/14
18:22
08/14/18
18:22
Upgrade
Nvidia rating change at Wells Fargo »

Nvidia double-upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

CVS

CVS Health

$71.39

1.88 (2.70%)

18:20
08/14/18
08/14
18:20
08/14/18
18:20
Hot Stocks
CVS Health says 'actively working' with Ohio Managed Medicaid clients »

"CVS Health is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

VRAY

ViewRay

$9.89

-0.01 (-0.10%)

18:18
08/14/18
08/14
18:18
08/14/18
18:18
Syndicate
ViewRay $125M Spot Secondary; price range $9.25-$9.50 »

Morgan Stanley, Jefferies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 04

    Sep

CRZO

Carrizo Oil & Gas

$24.31

0.62 (2.62%)

18:16
08/14/18
08/14
18:16
08/14/18
18:16
Syndicate
Carrizo Oil & Gas 9.5M share Spot Secondary; price range $22.90-$23.50 »

Citi and Goldman Sachs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 15

    Aug

WTW

Weight Watchers

$77.39

1.8 (2.38%)

18:12
08/14/18
08/14
18:12
08/14/18
18:12
Syndicate
Weight Watchers 6M share Block Trade; price range $76.00-$77.00 »

Morgan Stanley is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERI

Eldorado Resorts

$43.85

0.55 (1.27%)

, PAY

Verifone

$23.00

-0.02 (-0.09%)

18:05
08/14/18
08/14
18:05
08/14/18
18:05
Hot Stocks
S&P announces changes to S&P MidCap 400 index »

S&P Dow Jones Indices…

ERI

Eldorado Resorts

$43.85

0.55 (1.27%)

PAY

Verifone

$23.00

-0.02 (-0.09%)

ADNT

Adient

$42.65

0.19 (0.45%)

DCT

DCT Industrial

$65.28

-0.34 (-0.52%)

PLD

Prologis

$64.05

-0.38 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$116.73

0.7 (0.60%)

18:00
08/14/18
08/14
18:00
08/14/18
18:00
Hot Stocks
Celanese to increase price of acetate flake by 50c/kg »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

GDDY

GoDaddy

$75.81

0.52 (0.69%)

17:43
08/14/18
08/14
17:43
08/14/18
17:43
Syndicate
GoDaddy files to sell 10,398,942 shares of Class A common stock »

Selling stockholders are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAG

MAG Silver

$8.64

0.07 (0.82%)

17:41
08/14/18
08/14
17:41
08/14/18
17:41
Earnings
MAG Silver reports Q2 EPS (3c), consensus (2c) »

Reports cash and cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.